Vera Therapeutics, Inc.
The company is working to develop and commercialize innovative therapies for patients with severe immune disorders. Its lead product candidate is atacicept, a fusion protein that inhibits B-lymphocyte stimulatory factor and proliferation-inducing ligand (PI-ALD) for immunoglobulin A nephropathy (IgAN). It is also expected to be effective against systemic, severe lupus nephritis. A Delaware resident.
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 51 |
Founded | 2016 |
Financials | |
|---|---|
Market Capitalization | 2.00B |
Revenue | |
Operating Income | -101.87M |
Operating Margin | |
Net Income | -94.30M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4798 / 5373 |
Sector : Healthcare | 886 / 1144 |
Industry : Biotechnology | 454 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 1951 / 5565 |
Sector : Healthcare | 233 / 1182 |
Industry : Biotechnology | 79 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4715 / 5436 |
Sector : Healthcare | 881 / 1164 |
Industry : Biotechnology | 454 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4419 / 5330 |
Sector : Healthcare | 796 / 1174 |
Industry : Biotechnology | 366 / 667 |